Summit Therapeutics Inc. - 8-K Filing

Summit Therapeutics initiates global Phase III HARMONi-10 trial evaluating ivonescimab against durvalumab for Stage III non-small cell lung cancer.

SEC EDGAR ·

Tickers: $SMMT

Read the full article at SEC EDGAR

More Regulatory news